Moreover, reduction of KMO expression after its exposure to MCLs may serve as an exciting candidate in regulating the kynurenine pathway in tumour immunity (Fig. 5e) and opens up the possibility that disrupting the metabolism of kynurenines may be used to design novel and more effective treatment strategies. This evidence concerns the gene KMO and neoplasm.